/ /

  • linkedin
  • Increase Font
  • Sharebar

    New ocular allergy drug’s MOA targets inflammation

     

    Clinical assessment

    The phase IIa study was a randomized, parallel-group, double-masked, vehicle-controlled clinical trial of the effect of NS2 in 100 men and women in whom allergic conjunctivitis was induced using a conjunctival allergen provocation test (CAPT challenge). All subjects had at least a 2-year history of allergic conjunctivitis resulting from exposure to pollen from grass, trees, or ragweed.

    Related: How to improve diagnosis and treatment of allergy

    Dr. Clark reported that NS2 has a rapid onset of action, with positive effects visible within a few minutes of drug administration. Compared with the vehicle, the investigators saw significant differences (p < 0.05 for both comparisons) in ocular itching and tearing after NS2 treatment. Importantly, the effect of the drug over baseline symptoms was sustained for over 3 hours following the challenge.

    Dr. Clark noted that the effect persisted across all time points for all challenges despite a stronger than expected effect of the vehicle.

    Related: A new player in point-of-care allergy testing

    The subjects were treated with NS2 or vehicle QID for 16 days. CAPT challenges were performed on dosing days 1, 14, 15, and 16. The ocular itching and tearing were assessed on scales of 0 (indicating no symptoms) to 4 (indicating extreme symptoms).

    No safety concerns were noted during the trial and the patients tolerated the drug well. The only adverse effect was transient and generally mild stinging. Two patients dropped out of the study.

    Future considerations

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results